CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial.
about
From synovial tissue to peripheral blood: myeloid related protein 8/14 is a sensitive biomarker for effective treatment in early drug development in patients with rheumatoid arthritisWhy CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritisG protein signaling modulator-3: a leukocyte regulator of inflammation in health and diseaseAbrogation of CC chemokine receptor 9 ameliorates collagen-induced arthritis of miceA personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm.Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.Regulation of TNF-α with a focus on rheumatoid arthritis.Emerging therapies for rheumatoid arthritis.Advances in understanding the pathogenesis of autoimmune disorders: focus on chemokines and lymphocyte trafficking.Inflammatory Cell Migration in Rheumatoid Arthritis: A Comprehensive Review.Successes and failures of chemokine-pathway targeting in rheumatoid arthritis.Considerations About the Role of the CCR5 Gene in Juvenile Idiopathic Arthritis - Look at the Whole or Put All Parts Together?The multiple chemokine-binding bovine herpesvirus 1 glycoprotein G (BHV1gG) inhibits polymorphonuclear cell but not monocyte migration into inflammatory sites.What is the future of CCR5 antagonists in rheumatoid arthritis?Overcoming hurdles in developing successful drugs targeting chemokine receptors.The Role of Macrophages in the Response to TNF Inhibition in Experimental Arthritis.Protective role for CCR5 in murine lupus nephritis.CCR5 deficiency does not reduce hypertensive end-organ damage in mice.CCR5-Delta32: implications in SLE development.T Cells That Help B Cells in Chronically Inflamed Tissues
P2860
Q28542641-F959A043-1993-4441-91A4-847F46309B8FQ28742993-0E10546E-59DF-403A-B139-513E404F2476Q34066497-7BF4D740-AF95-4EB4-A0E3-65DC8DE038ADQ34363191-1BAE6E29-A623-42CC-8139-EFBAF3132518Q35835741-6FCE1D06-86DD-4AF1-AB47-AC596B37F542Q36084912-8B3C60C8-FA63-4E92-9B33-1FE0544CCCE6Q38102876-50E99FED-EACC-406A-A830-A06E72437FA0Q38110963-ADC18FD3-6415-4030-B218-4A18A3A21351Q38155907-0890E596-CBB6-4CC0-8151-45379BA7B890Q38618883-343CEA60-1E37-4E6E-A6A5-C9CC8A9A0609Q38647749-E271F2D4-6CAD-4382-9D0E-DD7ABF6B8763Q39979340-9A374FD1-00F2-48AD-A07F-C1E42F7EAB32Q41945153-51F28B9B-7AB8-49BF-B812-FB1F8C9C2216Q42326321-114F5898-5D5C-4333-BC72-E4805CFF8000Q46441158-05AEC7DD-BE15-4657-88B4-420F1E030AC1Q47390076-3C604294-E7CD-4B2A-8146-F2C46F9CE4C3Q47989935-02656E24-4690-4A28-84D3-DB8DDFC498B9Q53191263-1D3034C2-4D0B-44AB-9C69-47C3E7AE6023Q54688004-D9F15751-79F4-4F08-A939-D4FACC95EB17Q58712847-011E2F21-709F-49E9-BC4B-1B8A1A8E1454
P2860
CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
CCR5 blockade in rheumatoid ar ...... ebo-controlled clinical trial.
@en
CCR5 blockade in rheumatoid ar ...... ebo-controlled clinical trial.
@nl
type
label
CCR5 blockade in rheumatoid ar ...... ebo-controlled clinical trial.
@en
CCR5 blockade in rheumatoid ar ...... ebo-controlled clinical trial.
@nl
prefLabel
CCR5 blockade in rheumatoid ar ...... ebo-controlled clinical trial.
@en
CCR5 blockade in rheumatoid ar ...... ebo-controlled clinical trial.
@nl
P2093
P356
P1476
CCR5 blockade in rheumatoid ar ...... cebo-controlled clinical trial
@en
P2093
Arno W R van Kuijk
Barry Bresnihan
Christiaan van der Leij
Clarissa E Vergunst
Danielle M Gerlag
Juan J Gomez-Reino
Maarten C Kraan
Mario Maas
Paul P Tak
P304
P356
10.1136/ARD.2010.131235
P407
P577
2010-08-06T00:00:00Z